Quantum-Si (NASDAQ: QSI) is set to release its Q4 2025 earnings report on March 3, 2026, after the market closes. Analysts anticipate that the company will report a loss of $0.14 per share, alongside an estimated revenue of $0.762 million for the quarter. Investors and stakeholders can access details of the earnings call scheduled for 4:30 PM ET on the same day through the company’s earnings summary page.
Stock Performance and Insider Activity
On Friday, Quantum-Si’s stock opened at $0.96. Over the past year, it has fluctuated between a low of $0.89 and a high of $3.10. The company’s fifty-day moving average stands at $1.13, while the two-hundred-day moving average is $1.38. With a market capitalization of $206.09 million and a price-to-earnings ratio of -1.43, the stock has exhibited a beta of 2.98, indicating higher volatility compared to the market.
Recent insider transactions have drawn attention. On December 22, John S. Vieceli, an insider, sold 21,927 shares at an average price of $1.28, totaling $28,066.56. Following this sale, Vieceli retains 800,973 shares valued at approximately $1,025,245.44, marking a position decrease of 2.66%. In a similar transaction on the same day, CEO Jeffrey Alan Hawkins sold 23,707 shares for $30,344.96, reducing his ownership by 0.91% to 2,578,018 shares, worth about $3,299,863.04. Over the last ninety days, insiders have sold a cumulative total of 54,261 shares valued at $69,454, with insiders currently owning 30.04% of the company’s stock.
Institutional Investment Trends
Institutional investors have been active in trading Quantum-Si shares. Prudential Financial Inc. acquired a new stake in the second quarter valued at $25,000, while Cerity Partners LLC invested $29,000 during the same period. BNP Paribas Financial Markets bolstered its stake by 101.3% in the third quarter, bringing its total to 30,464 shares, worth approximately $43,000 after acquiring an additional 15,331 shares. Other notable transactions include Dimensional Fund Advisors LP purchasing a stake worth $34,000 and the State Board of Administration of Florida Retirement System acquiring shares valued at $45,000. Currently, institutional investors hold 39.90% of Quantum-Si stock.
Research analysts have also weighed in on Quantum-Si’s stock performance. Canaccord Genuity Group lowered its price target from $2.00 to $1.50 and maintained a “hold” rating in a report issued on December 22. Weiss Ratings reaffirmed a “sell (d-)” rating on December 29. Presently, two analysts have rated the stock as a Buy, one as a Hold, and one as a Sell. According to MarketBeat.com, Quantum-Si holds an average rating of “Hold” with a consensus price target of $3.55.
Quantum-Si Inc., headquartered in Guilford, Connecticut, specializes in life sciences instrumentation. The firm focuses on developing next-generation proteomics solutions utilizing semiconductor sequencing technology. Its principal product is a proprietary single-molecule protein sequencing platform that employs silicon-based sensor chips to convert protein data into digital signals. This approach aims to enhance sensitivity, achieve single-amino-acid resolution, and ensure deep proteome coverage while potentially lowering costs compared to traditional mass spectrometry methods.
The company’s roadmap includes plans for the development and commercialization of an integrated system comprising instruments, consumable reagents, and proprietary data analysis software. As Quantum-Si prepares for its earnings report, stakeholders will be keen to see how the company’s innovative technologies and market strategies evolve in a competitive landscape.
